Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.
Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.
Summit Therapeutics has appointed Dr. Urte Gayko to its Board of Directors, effective immediately. Dr. Gayko brings over 20 years of expertise in regulatory and clinical development, having held key roles at companies like Nektar Therapeutics and Pharmacyclics. Her experience is expected to bolster Summit’s mission to commercialize its drug candidates, particularly ridinilazole, which is in a Phase III trial for Clostridioides difficile infection. The company is focused on developing innovative therapies while addressing serious unmet medical needs.
Summit Therapeutics (NASDAQ: SMMT) has announced the appointment of Kenneth A. Clark, JD, to its Board of Directors, effective immediately. Clark, a partner at Wilson Sonsini Goodrich & Rosati, brings over 35 years of experience in biotech strategic partnerships and mergers. His leadership is expected to guide Summit in achieving its aggressive goals and expanding its product pipeline targeting unmet medical needs. In conjunction with this appointment, Ramses Erdtmann will be stepping down from the Board. Clark's expertise is seen as a valuable asset for Summit's mission of enhancing patient quality of life.
Summit Therapeutics (NASDAQ: SMMT) presented an ePoster at IDWeek 2021 highlighting the novel mechanism of action of ridinilazole, its investigational antibiotic for Clostridioides difficile infections. The Phase III trial, Ri-CoDIFy, aims to demonstrate ridinilazole's superiority over vancomycin. The ePoster reveals evidence from high-resolution imaging of ridinilazole binding to bacterial DNA, underscoring its potential as the first new antibiotic mechanism approved in over a decade. Ridinilazole could play a significant role in addressing antibiotic resistance.
Summit Therapeutics Inc. (NASDAQ: SMMT) reported its Q2 2021 financial results, revealing cash and cash equivalents of $103.4 million, up from $66.4 million at year-end 2020. The company raised $75 million via a Rights Offering, primarily used to repay previous debt. However, net losses increased to $24.4 million for Q2 2021 from $15.3 million in Q2 2020. Notably, BARDA provided support for clinical trials with funding of up to $72.5 million. The company also advanced its antibiotic SMT-738 and expanded its pipeline into oncology and microbiome health.
On August 11, 2021, Summit Therapeutics (NASDAQ: SMMT) announced its decision to combine two ongoing Phase III clinical trials evaluating ridinilazole against vancomycin for Clostridioides difficile infections. Current enrollment stands at 753 patients, allowing for a prospective planned analysis. Ridinilazole aims to demonstrate superiority in sustained clinical response over vancomycin, although it remains unapproved. The company’s Phase II data highlighted ridinilazole's minimal impact on the gut microbiome. The trials are funded in part by BARDA, reflecting confidence in their potential outcomes.
Summit Therapeutics showcased three notable ePosters at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) focused on its investigational drug, ridinilazole, for treating Clostridioides difficile infections. Key findings include ridinilazole's ability to preserve gut microbiota without increasing antibiotic resistance, and its novel mechanism of action targeting C. difficile DNA. Amid two pivotal Phase III trials, these results reinforce ridinilazole's potential as a first-line treatment, minimizing disease recurrence and aligning with regulatory efforts for its approval.
Summit Therapeutics (NASDAQ: SMMT) announced that its scientific team will present significant research at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) from July 9-12, 2021. Highlights include a Top Rated ePoster on the impact of the antibiotic Ridinilazole on gut microbiota. Ridinilazole is in Phase III trials aimed at treating and preventing recurrence of Clostridioides difficile infection (CDI), a serious illness affecting over 500,000 annual cases in the U.S. The company aims to provide effective therapies with minimal side effects.
Summit Therapeutics Inc. (NASDAQ: SMMT) will join the Russell 3000® Index after the annual reconstitution on June 28, 2021. This addition, determined by market capitalization, signifies recognition of the company's progress in addressing unmet medical needs. The Russell 3000® Index, encompassing 4,000 large U.S. stocks, facilitates investment strategies for managers, with over $10.6 trillion benchmarks tied to it. Summit Therapeutics aims to lead in treatments for infectious diseases, focusing on novel antibiotics aligned with the human microbiome.
Summit Therapeutics Inc. (NASDAQ: SMMT) is set to hold its virtual Annual Shareholders’ Meeting on June 16, 2021, at 1:00 pm ET. Shareholders and interested parties are invited to attend through a provided online link. The company's innovative Discuva Platform aims to advance treatments for infectious diseases, focusing on Clostridioides difficile infections. Summit's lead candidate, ridinilazole, is currently in pivotal Phase 3 trials, while SMT-738 is in the IND-enabling phase for multidrug-resistant infections. Regulatory approvals are essential for commercialization.
Summit Therapeutics (NASDAQ: SMMT) has selected SMT026738, a new preclinical candidate targeting multidrug-resistant infections, particularly carbapenem-resistant Enterobacteriaceae (CRE). The company received an initial award of up to $4.1 million from CARB-X to advance SMT-738 through preclinical and Phase 1a trials, with potential additional funding of $3.7 million based on milestones. SMT-738 employs a novel mechanism using LolCDE, targeting pathogens like Escherichia coli and Klebsiella pneumoniae, offering hope against infections with limited treatment options due to antibiotic resistance.